Canakinumab is an interleukin-1β (IL-1β) blocker used for diseases such as cryopyrin-associated periodic syndromes (CAPS), hyperimmunoglobulin D syndrome (HIDS), mevalonate kinase deficiency (MKD), and familial Mediterranean fever (FMF).

How effective is Canakinumab (ILARIS) in treatment?

Canakinumab is a biological agent targeting specific inflammatory diseases. It works by inhibiting the activity of IL-1. IL-1 is a cytokine that plays an important role in various inflammatory diseases. Canakinumab can reduce inflammatory responses and control disease symptoms.

Canakinumab has a significant therapeutic effect, but some side effects may occur during use, such as diarrhea and nasopharyngitis. Before using the drug, patients should fully understand information such as its usage and dosage, adverse reactions, and drug interactions, and use it rationally under the guidance of doctors.

What is the latest price of Canakinumab in 2025?

The price of Canakinumab is not fixed and may vary due to various factors. The following are its reference prices and related suggestions:

The latest price of Canakinumab

The price is for patients' reference only. The actual purchase price may vary. Please refer to the final purchase price. Suggestions for purchasing Canakinumab

Canakinumab has not yet been launched in China, so patients cannot buy it in China. They can purchase it through legal and regular online pharmacies or overseas channels. When purchasing, patients should pay attention to choosing regular channels, carefully check the drug information, and ensure the quality and authenticity of the drug.

Precautions for Canakinumab

Patients should be aware of the precautions for Canakinumab to avoid possible risks:

Severe infections

Canakinumab can inhibit part of the function of the immune system, reduce the patient's resistance to infections, and may increase the risk of severe or even fatal infections in patients. During the use of Canakinumab, patients should avoid close contact with known infected persons.

Patients with active infections or a history of infections should use Canakinumab with caution. If patients experience infection symptoms such as fever, chills, cough, shortness of breath, diarrhea, or skin ulcers, they should seek medical attention in time and inform the doctor that they are using Canakinumab.

Immunosuppression

Canakinumab reduces inflammation and immune responses by inhibiting the activity of interleukin-1 (IL-1), which can also reduce the overall function of the immune system, possibly increasing the patient's susceptibility to infections, including bacterial and viral infections.

Long-term use of immunosuppressive drugs may increase the risk of malignant diseases. Patients should have regular physical examinations during the use of Canakinumab.

Warm reminder: Before using Canakinumab, patients must consult a doctor to understand the usage of the drug and possible risks. When using Canakinumab, it is necessary to strictly follow the doctor's advice and precautions, and seek medical treatment in time for any problems.